Literature DB >> 750188

A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids.

F Z Stanczyk, P F Brenner, D R Mishell, A Ortiz, E K Gentzschein, U Goebelsmann.   

Abstract

A sensitive and reliable radioimmunoassay (RIA) for the measurement of norethindrone (NET) in serum has been established employing anti-11 alpha-hydroxynorethindrone 11-hemisuccinyl-bovine serum albumin serum in conjunction with norethindrone-3-(0-carboxymethyl) oximino-[125I]-iodohistamine. Of a number of ring A reduced NET metabolites, only 17 beta-hydroxy-17 alpha-ethinyl-5 beta-estran-3-one (43%) and 17 alpha-ethinyl-5 alpha-estrane-3 beta, 17 beta-diol (15.7%) cross-reacted appreciably in this RIA. Ethinyl estradiol (EE2) and mestranol (MEE2) exhibited cross-reactions of only 1.1 and 0.4%, respectively. Serum NET levels were measured in four groups of 3 women, each ingesting either 1 mg NET plus 0.05 mg MEE2 (Norinyl 1 + 50 or Ortho Novum 1/50), 0.5 mg NET plus 0.035 mg EE2 (Brevicon) or only 0.35 mg NET (Micronor) daily for 5 consecutive days. Peak serum NET levels were observed within 1/2 to 4 hours after oral intake and fell precipitously thereafter. After reaching a maximum, serum NET concentrations declined in a manner consistent with at least two disposition phases. The average half-life for the first disposition phase was 2.3, 3.4, 3.9 and 4.4 hours in subjects ingesting Norinyl 1 + 50, Ortho Novum 1/50, Brevicon and Micronor, respectively. Peak and 3-hour post-ingestion serum NET concentrations were dose-related but showed considerable subject-to-subject variations. Following discontinuation of tablet intake, serum NET levels remained detectable (greater than 0.05 ng/ml) for at least 5 days in all 3 women who had taken Ortho Novum 1/50, but in none of the other 9 volunteers. These results suggest that different preparations of identical doses and combinations of oral contraceptive steroids may yield different serum NET profiles. However, due to considerable subject-to-subject variations, larger numbers of subjects are required for a conclusive investigation.

Entities:  

Keywords:  Clinical Research; Contraception; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Contraceptive Agents--side effects; Ethinyl Estradiol; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Laboratory Procedures; Mestranol--side effects; Norethindrone--administraction and dosage; Norethindrone--analysis; Norethindrone--side effects; Norethynodrel--side effects; Oral Contraceptives; Oral Contraceptives, Combined; Progestins, Low-dose--side effects; Research Methodology

Mesh:

Substances:

Year:  1978        PMID: 750188     DOI: 10.1016/0010-7824(78)90046-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

Review 1.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

2.  Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy.

Authors:  Barent N DuBois; Jessica Atrio; Frank Z Stanczyk; Ganesh Cherala
Journal:  Contraception       Date:  2014-08-30       Impact factor: 3.375

3.  Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.

Authors:  Jessica Atrio; Frank Z Stanczyk; Michael Neely; Ganesh Cherala; Andrea Kovacs; Daniel R Mishell
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.